evipedia.ai
← Back

Magnesium L-Threonate for Health & Longevity

Evidence Review created on 10/21/2026 using AI4L / Opus 5.5

Also known as: Magnesium Threonate, MgT, Magtein, L-Threonic Acid Magnesium Salt, L-TAMS, MMFS-01, ClariMem, Magnesium L-Threonate Monohydrate

Motivation

Magnesium L-threonate is a dietary supplement that pairs the mineral magnesium with threonate, a natural breakdown product of vitamin C. It was designed to carry magnesium into the brain more readily than common magnesium supplements, on the idea that brain magnesium helps maintain the connections between nerve cells that support learning and memory.

The compound came out of university laboratory work in rodents roughly fifteen years ago and later spread through popular sleep and brain-health routines. Most human studies so far have been small and short, and many were paid for by the companies that own or sell the ingredient, which has drawn both strong interest and pointed skepticism.

This review examines what the human and laboratory evidence shows about magnesium L-threonate for memory, sleep and long-term brain health, which risks and interactions it carries, and how it is used in practice by adults who are weighing it as part of a longevity-focused routine.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and foundational research that give a high-level view of magnesium L-threonate.

Only four items qualify. Andrew Huberman’s “Toolkit for Sleep” newsletter repeats his episode’s dosing line without further discussion, so it is cited under Therapeutic Protocol rather than listed separately here. Peter Attia’s dedicated magnesium episode (“Ask Me Anything” #54) discusses magnesium L-threonate but is subscriber-only beyond a topic outline, so it could not be verified as an openly accessible resource. Chris Kresser’s site contains only a single-sentence mention by a podcast guest, and Lifespan.io offers only a one-line news-roundup entry; neither discusses the compound in depth, so the list is not padded with them.

Grokipedia

  • Magnesium L-threonate

    AI-generated overview of chemistry, development history, trials and dosing; useful for orientation, but it includes a “top-rated brands” list and its claims need checking against primary studies.

Examine

  • Magnesium

    Examine has no standalone threonate page; its magnesium page covers forms, dosing and safety and links an FAQ judging threonate research highly limited, industry-funded and insufficient to confirm efficacy.

ConsumerLab

Systematic Reviews

No systematic reviews or meta-analyses for Magnesium L-Threonate were found on PubMed as of October 21, 2026.

Mechanism of Action

Magnesium is an enzyme cofactor and natural blocker of the NMDA (N-methyl-D-aspartate) receptor, a glutamate-gated channel central to learning. Brain magnesium helps set how strongly synapses (connections between nerve cells) respond to repeated signals.

  • Threonate as a carrier: In rats, magnesium L-threonate raised cerebrospinal fluid (CSF, the fluid bathing the brain) magnesium, synapse density and memory (Slutsky et al., 2010). In cultured neurons, threonate raised intracellular magnesium via GLUT transporters (proteins that move sugars into cells); other magnesium salts did not (Sun et al., 2016). Both come from the developer’s laboratory.
  • Downstream effects (animal): More NR2B-type NMDA receptors (a plasticity-linked subunit) and stronger long-term potentiation (lasting synapse strengthening) (Slutsky et al., 2010), plus less TNF-α (an inflammatory signal) after nerve injury (Wang et al., 2013).
  • Competing view: No human study has measured brain magnesium after threonate. In the Neurocentria-funded trial, plasma and red-blood-cell magnesium did not differ from placebo at 12 weeks (Liu et al., 2016). A rat study involving a commercial research firm found magnesium acetyl taurate raised tissue magnesium more (Kumar et al., 2026).
  • Pharmacology: Each gram supplies about 75 mg elemental magnesium (Hausenblas et al., 2024, AIDP-funded, corrected 2025). Calcium L-threonate data show threonate peaking about 2 hours after intake, half-life near 2.5 hours (Wang et al., 2011). Kidneys regulate magnesium excretion; threonate’s human metabolism is poorly characterized, with no known cytochrome P450 (liver drug-metabolizing enzyme) role. Effects are broad, not receptor-selective.

Historical Context & Evolution

Magnesium L-threonate was created around 2009–2010 by Guosong Liu’s group at the Massachusetts Institute of Technology, continued at Tsinghua University, to raise brain magnesium; its original intended use was enhancing learning and memory, first shown in rats (Slutsky et al., 2010). Lab-linked companies commercialized it: Magceutics licensed it as Magtein for supplements, and Neurocentria, Liu’s company, pursued it as a drug candidate (MMFS-01).

It was considered for health optimization because conventional magnesium salts barely change cerebrospinal fluid magnesium, while threonate appeared to bypass this limit in animals. A U.S. Food and Drug Administration “no questions” letter on a generally recognized as safe (GRAS) notice followed in 2014 (FDA GRAS Notice 499).

A 2013 Alzheimer’s mouse paper was withdrawn by its authors (retraction notice); a revised version from Liu’s laboratory appeared in 2014 (Li et al., 2014). The first human trial (2016) reported better composite cognition in older adults, though placebo responses swamped its sleep and anxiety endpoints (Liu et al., 2016).

Interest grew through popular sleep protocols (Toolkit for Sleep). Recent industry-funded trials reported cognitive gains and gains on some sleep measures (Hausenblas et al., 2024; Lopresti & Smith, 2025), while Chinese hospital trials without disclosed industry funding gave mixed results: one found no effect on pain, sleep or cognition (Ni et al., 2023), and another reported smaller opioid dose increases (Wu et al., 2023). The European Union authorized it as a novel food in 2024 (Commission Implementing Regulation (EU) 2024/2694). The question remains open rather than settled.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: each human outcome rests on one or two small, short, mostly industry-funded trials, and the consistently replicated findings come from rodent studies.

Medium 🟩 🟩

Cognitive Performance ⚠️ Conflicted

Two placebo-controlled trials from separate groups reported better composite cognition: Liu’s Neurocentria-funded trial in 44 adults aged 50–70 with memory complaints (Liu et al., 2016), and Lopresti’s Threotech-funded trial in 100 poor sleepers aged 18–45 (Lopresti & Smith, 2025; corrected 2026 without changing results). An independent breast cancer trial found no difference on a telephone screening test (Ni et al., 2023); a Neurocentria-supported schizophrenia trial posted untested working-memory scores (NCT02237235); a Magceutics-supported open-label (unblinded, no placebo) dementia study showed no improvement (NCT02210286). Net: a modest industry-funded signal, weakly contested.

Magnitude: Composite cognitive score improved more than placebo by Cohen’s d (a standardized effect size) 0.91, 95% CI (confidence interval, the plausible range) 0.27–1.51, at 12 weeks (Liu); the Total Cognition Composite improved more than placebo, p (probability the difference arose by chance) = 0.043, equivalent to an estimated cognitive age 7.5 years younger at 6 weeks (Lopresti).

Relief of Opioid-Induced Constipation ⭕️ Not Central to Health & Longevity

In 83 patients with advanced cancer taking oral opioids, 1.5–2.0 g daily for 12 weeks lowered constipation scores versus placebo from day 7 onward (Wu et al., 2023). This was a secondary outcome of one trial, and baseline constipation was worse in the threonate group, requiring statistical adjustment. Any magnesium salt can draw water into the bowel, so the effect is likely not unique to threonate. It bears on bowel comfort during opioid therapy rather than on longevity.

Magnitude: Adjusted Wexner score (a constipation severity scale; higher is worse) 12.81 with threonate vs 17.78 with placebo at day 21 (p < 0.001).

Low 🟩

Sleep Quality ⚠️ Conflicted

Two industry-funded trials found most sleep scores no better than placebo, with gains on a few (Hausenblas et al., 2024, corrected 2025; Lopresti & Smith, 2025, corrected 2026). An independent trial and a Momentous-co-sponsored blend found none (Ni et al., 2023; Mastrofini et al., 2026). Net: few measures improved.

Magnitude: Insomnia Severity Index fell from 12.32 to 7.86 with threonate and from 12.57 to 9.39 with placebo; the between-group difference was not significant (p = 0.39) (Hausenblas); the abstract’s “improved sleep quality” rests on wake-up behavior and ring-measured sleep-stage scores, not on the insomnia index.

Mood, Anxiety and Daytime Energy ⚠️ Conflicted

One industry-funded trial reported better alertness, mood and energy ratings than placebo (Hausenblas et al., 2024, corrected 2025). Anxiety and depression scores did not separate from placebo in three other trials (Liu et al., 2016; Wu et al., 2023; Ni et al., 2023). Net: inconsistent, mostly null.

Magnitude: Waking “mentally alert” rating rose from 2.87 to 3.58 with threonate vs 2.64 to 3.00 with placebo (p = 0.003), while total mood disturbance did not differ (p = 0.48) (Hausenblas).

Cancer Pain and Opioid Requirements ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

In advanced cancer, threonate slowed the rise in daily morphine dose over 90 days without changing pain scores (Wu et al., 2023). After breast cancer surgery, 12 weeks did not prevent persistent pain (Ni et al., 2023). Net: one positive, one null trial; bears on cancer pain care.

Magnitude: Increase in daily morphine dose by day 90 was 21.20 mg with threonate vs 40.44 mg with placebo (p < 0.01) (Wu); persistent pain at 6 months affected 31% (15/48) with threonate vs 26% (16/61) with placebo (p = 0.67) (Ni).

Adult Attention-Deficit/Hyperactivity Disorder Symptoms ⭕️ Not Central to Health & Longevity

In an open-label study of 15 adults with attention-deficit/hyperactivity disorder, symptom ratings improved over 12 weeks (Surman et al., 2021). The developer collaborated, and no controlled trial has followed. It bears on attention disorders rather than longevity.

Magnitude: 47% of participants met the study’s response criteria (no control group).

Blood Pressure Support From Magnesium Repletion

Across 34 trials of other magnesium salts, supplementation modestly lowered blood pressure (Zhang et al., 2016). This evidence is indirect: no threonate trial measured blood pressure, and standard threonate servings supply less magnesium than the median dose tested.

Magnitude: Systolic blood pressure fell 2.00 mm Hg (95% CI 0.43–3.58) and diastolic 1.78 mm Hg (95% CI 0.73–2.82) more than placebo at a median 368 mg/day of magnesium from other salts.

Speculative 🟨

Synapse Preservation and Protection Against Neurodegeneration

In rodents, threonate preserved synapses and memory in an Alzheimer’s model and after nerve injury (Li et al., 2014; Wang et al., 2013). Basis: animal work only, the Alzheimer’s data from the developer’s laboratory.

Autonomic Recovery During Sleep

One trial found lower sleeping heart rate and higher heart rate variability (beat-to-beat timing variation reflecting relaxation) than placebo (Lopresti & Smith, 2025, corrected 2026). These are unvalidated markers from a single study.

Benefit-Modifying Factors

  • Genetic variants: No genotype-guided threonate data exist. Loss-of-function variants in MAGT1 (a magnesium transporter gene) cause XMEN disease (an inherited immune deficiency); threonate did not correct its immune defects in a crossover trial (each participant received both treatments) (Chauvin et al., 2022).
  • Baseline magnesium status: People with low magnesium intake may gain most, but no threonate trial selected for low magnesium. In Liu’s trial, a rise in red-blood-cell magnesium tracked response, though its table shows no between-group difference (Liu et al., 2016).
  • Sex: Trials enrolled mostly women (71% in Liu et al., 2016, 79% in Hausenblas et al., 2024) and reported no sex-specific analyses. A completed trial designed to compare sexes has not posted results (NCT07706283).
  • Pre-existing conditions: Cognitive and sleep signals came from people with memory complaints, poor sleep or anxiety; no benefit appeared after breast cancer surgery (Ni et al., 2023). Kidney disease increases magnesium retention, shifting the benefit–risk balance.
  • Age: Older participants improved more in a threonate combination-formula trial using Magceutics-supplied product (Zhang et al., 2022) and in Lopresti’s exploratory analysis (Lopresti & Smith, 2025, corrected 2026). Older adults also more often have low magnesium and reduced kidney clearance.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has been shown in excess of placebo in threonate trials from more than one research group.

Medium 🟥 🟥

No risk reaches Medium: threonate-specific safety data consist of adverse-event tallies from small trials of about 3 months or less, none showing excess over placebo.

Low 🟥

Gastrointestinal Upset ⚠️ Conflicted

Magnesium salts commonly cause loose stools; a Cochrane review found mostly gastrointestinal events (Garrison et al., 2020). In threonate trials, such events did not differ significantly from placebo (Liu et al., 2016; Lopresti & Smith, 2025, corrected 2026). Net: likely mild and uncommon at standard doses.

Magnitude: Gastrointestinal adverse events affected 20.0% (5/25) with threonate vs 15.4% (4/26) with placebo (p = 0.726) (Liu).

Hypermagnesemia With Impaired Kidney Function

Hypermagnesemia (dangerously high blood magnesium causing weakness, low blood pressure and slowed heartbeat) occurred in four older adults with kidney dysfunction taking magnesium oxide laxatives (Yamaguchi et al., 2019). Evidence is indirect: a different salt at higher doses; no threonate case is reported.

Magnitude: Four cases, one fatal, all in patients over 65 with renal dysfunction (case series, no control group).

Speculative 🟨

Unknown Long-Term Effects

Trials lasted at most 90 days (Wu et al., 2023; NCT02210286), so longer use is uncharacterized. The European Food Safety Authority judged 2.7 g/day threonate safe (EFSA, 2024). Basis: absent long-term data.

Additive Lowering of Heart Rate and Blood Pressure

One trial observed lower sleeping heart rate (Lopresti & Smith, 2025, corrected 2026); magnesium modestly lowers blood pressure. Effects could add to blood-pressure drugs. Basis is mechanistic only.

Risk-Modifying Factors

  • Genetic variants: No pharmacogenetic data exist for threonate. Rare inherited magnesium-handling disorders, such as MAGT1 variants in XMEN disease, alter magnesium transport; threonate caused no reported harm in an XMEN trial (Chauvin et al., 2022).
  • Baseline biomarkers: Reduced kidney function (low eGFR, estimated glomerular filtration rate, a kidney-filtering measure) or high-normal serum magnesium raises the risk of magnesium excess; low baseline magnesium lowers it.
  • Sex: No sex differences in adverse events have been reported. Use during pregnancy and breastfeeding is excluded under the European Union authorization (Commission Implementing Regulation (EU) 2024/2694).
  • Pre-existing conditions: Kidney disease and slowed bowel transit raise magnesium-excess risk (Yamaguchi et al., 2019); myasthenia gravis (autoimmune muscle weakness) and heart conduction block (slowed electrical signaling through the heart) are theoretical concerns.
  • Age: Hypermagnesemia cases clustered in adults over 65 with declining kidney function and impaired ability to report symptoms (Yamaguchi et al., 2019).

Key Interactions & Contraindications

No human interaction study of magnesium L-threonate exists; entries are extrapolated from studies or labels of other magnesium products unless marked theoretical.

Prescription drugs

  • Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin): Caution. A magnesium-aluminum antacid given 2 hours before ciprofloxacin cut its absorption to 23% (Nix et al., 1989), risking treatment failure. Antacid given 6 hours before or 2 hours after did not affect absorption.
  • Integrase inhibitors (drugs against HIV, the human immunodeficiency virus) (dolutegravir, bictegravir): Caution. A magnesium-aluminum antacid taken together cut dolutegravir exposure 74%, versus 26% dosed 2 hours apart (Patel et al., 2011), risking treatment failure. Dosing 2 hours before or 6 hours after limits this.
  • Tetracycline antibiotics (doxycycline, minocycline): Caution. An aluminum-magnesium antacid cut doxycycline exposure from 38.6 to 6.0 mg·h/L, leaving levels too low to treat infection (Deppermann et al., 1989); the doxycycline label lists the same interaction (DORYX MPC label). Separating doses by several hours limits this.
  • Bisphosphonates (bone-loss drugs) (alendronate, risedronate): Caution. The alendronate label states that calcium, antacids and other mineral-containing products interfere with absorption and advises waiting at least 30 minutes after the drug (FOSAMAX label); otherwise bone protection may fall.
  • Gabapentin (a nerve-pain and seizure drug): Caution. A magnesium-aluminum antacid lowered gabapentin bioavailability by about 20%, and the label advises taking gabapentin at least 2 hours after it (NEURONTIN label); reduced absorption may weaken pain or seizure control.
  • Thyroid hormone (levothyroxine): Monitor. The levothyroxine label lists magnesium-containing antacids as reducing its absorption and advises monitoring (SYNTHROID label); lower absorption can undertreat hypothyroidism (an underactive thyroid). Separating doses by several hours limits this.
  • Proton pump inhibitors (acid-reducing drugs) (omeprazole, pantoprazole): Monitor. Their use is linked to low magnesium (adjusted odds ratio, a measure of relative odds, 1.71) (Srinutta et al., 2019); threonate’s small magnesium dose may not offset this; serum magnesium checks detect it.
  • Loop or thiazide diuretics (fluid-removing drugs) (furosemide, hydrochlorothiazide): Monitor (theoretical). These increase urinary magnesium loss, which threonate’s small dose may not offset, leaving deficiency uncorrected; serum magnesium checks detect it.
  • Potassium-sparing diuretics (fluid-removing drugs that retain potassium) (amiloride, spironolactone): Monitor (theoretical). These reduce urinary magnesium loss, so added magnesium could accumulate, especially with reduced kidney function; periodic serum magnesium checks detect accumulation.
  • Antihypertensives (blood-pressure drugs), including calcium channel blockers (amlodipine, nifedipine): Monitor (theoretical). Magnesium modestly lowers blood pressure and calcium channel blocker users were excluded from the first trial (Liu et al., 2016); additive lowering could cause dizziness. Home blood-pressure tracking detects this.

Over-the-counter medications

  • Magnesium-containing antacids and laxatives (magnesium hydroxide, magnesium citrate): Caution (theoretical). These add magnesium load, raising the risk of diarrhea and, with poor kidney function, hypermagnesemia. All sources count toward the supplemental total.

Supplements

  • Other magnesium supplements (glycinate, citrate, oxide): Caution (theoretical). Combined intake can exceed the 250 mg/day supplemental upper level used in Europe (EFSA, 2024), causing loose stools. Totaling all supplemental magnesium prevents this.
  • Calcium, iron and zinc supplements: Monitor (theoretical). These minerals may compete with magnesium for absorption, reducing uptake of each. Spacing doses about 2 hours apart limits this.
  • Sleep-supporting supplements (L-theanine, apigenin, glycine, melatonin): Monitor (theoretical) for additive drowsiness. An evening threonate–theanine–apigenin blend showed no excess harm but no benefit (Mastrofini et al., 2026).
  • Blood-pressure-lowering supplements (potassium, fish oil, beetroot nitrate): Monitor (theoretical) for additive blood-pressure lowering and dizziness, detectable by home blood-pressure tracking.

Other interventions

  • Alcohol: Monitor (theoretical). Heavy drinking increases urinary magnesium loss, which may blunt any magnesium-status benefit.
  • NMDA-blocking drugs (memantine, ketamine): Monitor (theoretical). Magnesium also blocks NMDA receptors; additive central effects are possible but undocumented, so prescribers are commonly informed.

Populations who should avoid Magnesium L-Threonate:

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Separate from mineral-binding drugs: Taking fluoroquinolones or dolutegravir 2 hours before or 6 hours after threonate prevents antibiotic or antiretroviral failure from reduced absorption (Nix et al., 1989; Patel et al., 2011).
  • Cap total supplemental magnesium: Keeping all supplemental magnesium at or below 250 mg/day, the European upper level (EFSA, 2024), prevents diarrhea and magnesium excess; 2 g threonate supplies about 145 mg.
  • Check kidney function first: Measuring creatinine and eGFR before starting, and not using threonate when serum creatinine is 2.0 mg/dL or higher (Liu et al., 2016), prevents hypermagnesemia.
  • Stop if magnesium runs high: Stopping and seeking medical advice when serum magnesium exceeds 0.95 mmol/L, the conventional upper reference limit (Costello et al., 2016), or when weakness or slow heartbeat appears prevents toxicity.
  • Split doses and take with food: Morning and evening doses with meals reduce gastrointestinal upset; food also increased threonate absorption (Wang et al., 2011).
  • Monitor blood pressure on antihypertensives: Weekly home blood-pressure checks in the first month detect additive lowering before it causes dizziness.
  • Reassess at 12 weeks: Because effects beyond about 3 months are unknown, a review of benefit, tolerance and labs at that point limits exposure to uncharacterized long-term risk.

Therapeutic Protocol

Other parameters without a citation (e.g., timing, cycling, titration steps) reflect common practice.

  • Standard trial dose: 2 g/day of Magtein (about 145 mg elemental magnesium), as 1 g in the morning and 1 g two hours before bed, for 6 weeks (Lopresti & Smith, 2025, corrected 2026).
  • Developer’s weight-based dose: About 25 mg/kg/day: 1.5 g/day for 50–70 kg or 2 g/day for 70–100 kg, for 12 weeks (Liu et al., 2016); designed by Neurocentria.
  • Lower sleep-focused dose: 1 g/day (about 75 mg magnesium) taken 2 hours before bed for 21 days (Hausenblas et al., 2024, corrected 2025); sponsored by AIDP.
  • Practitioner sleep protocol: Andrew Huberman lists 145 mg magnesium threonate 30–60 minutes before bed, introducing one supplement at a time (Toolkit for Sleep); whether 145 mg means compound or elemental magnesium is unstated.
  • Alternative approach: Glycinate, citrate or other salts deliver more elemental magnesium per gram at lower cost; no published human trial compares them with threonate for brain outcomes, though one is recruiting (NCT07640685).
  • Time of day: Evening dosing for sleep goals; morning plus evening dosing for cognitive goals, matching the trials above.
  • Half-life: Threonate’s plasma half-life is about 2.5 hours (Wang et al., 2011); the kidneys tightly regulate blood magnesium, so twice-daily dosing aims for steadier exposure.
  • Single vs split dosing: Cognitive trials split the dose twice daily; sleep trials used one evening dose. Splitting may also improve gastrointestinal tolerance.
  • Genetic polymorphisms: No variant is known to change threonate dosing; rare inherited magnesium-transport disorders need specialist management rather than threonate (Chauvin et al., 2022).
  • Sex differences: No sex-specific dosing data exist; trials were mostly female. The weight-based scheme above adjusts for body size.
  • Age: Older adults responded in the 50–70 age trial at weight-based doses (Liu et al., 2016); above 65, kidney function is commonly checked before starting.
  • Baseline biomarkers: With low serum magnesium, threonate’s small elemental content may not correct deficiency; higher-magnesium salts are commonly added or substituted.
  • Pre-existing conditions: Kidney impairment calls for avoidance or physician supervision; cognitive and sleep complaints were the populations where signals appeared.

Discontinuation & Cycling

  • Lifelong or short-term: No data support lifelong use; published trials lasted 2 weeks to 90 days, so longer use is an extrapolation and is commonly framed as an open-ended trial with periodic review.
  • Withdrawal effects: None reported in any trial; magnesium is an essential nutrient without known dependence or rebound.
  • Tapering: Not required; stopping abruptly is common practice.
  • Cycling: No evidence shows cycling maintains efficacy or that tolerance develops; continuous daily use matched all trial designs.
  • Stop rule: A 6–12 week trial with defined goals (sleep tracking, cognitive testing) followed by stopping if no change is a common approach.

Sourcing and Quality

  • Branded ingredient: Magtein is the patented form used in nearly all trials, supplied by Threotech and AIDP; generic “magnesium threonate” lacks trial data and may differ in purity.
  • Elemental magnesium content: About 7–8% of the compound weight is magnesium (about 145 mg per 2 g); reputable labels state both compound and elemental amounts.
  • Third-party testing: Quality markers include USP (U.S. Pharmacopeia) Verified, NSF International Certified for Sport or Informed Sport seals; ConsumerLab names a Top Pick for magnesium L-threonate in its members-only magnesium review.
  • Reputable brands: Magtein appears in products from Doctor’s Best, Double Wood, Jarrow Formulas, Life Extension (Neuro-Mag), Momentous, NOW and Source Naturals, per ConsumerLab’s public summary.
  • Combination products: Many products add L-theanine, apigenin, phosphatidylserine or vitamins; blend trials (Zhang et al., 2022; Mastrofini et al., 2026) do not isolate threonate’s effect.
  • Purity specification: The authorized ingredient may contain up to 1% oxalic acid, judged not a safety concern (EFSA, 2024); reputable suppliers provide a certificate of analysis.

Practical Considerations

  • Time to effect: Some sleep-related and alertness measures separated from placebo by 7–14 days (Hausenblas et al., 2024, corrected 2025); cognitive changes were measured at 6–12 weeks.
  • Common pitfalls: Mistaking 2 g of compound for 2 g of magnesium; expecting threonate alone to correct deficiency; stacking with other magnesium products; taking it alongside antibiotics; judging a blend’s results as threonate’s.
  • Regulatory status: A dietary supplement in the United States, with a 2014 “no questions” GRAS notice for food use (FDA GRAS Notice 499); a European Union novel food for adults since 2024 (Commission Implementing Regulation (EU) 2024/2694). It is not an approved drug.
  • Cost and accessibility: Widely available; costlier per milligram of magnesium than common salts. No insurer or health system pays for either, so no institutional payer incentive favors one form.
  • Industry-funded evidence: Most positive trials were funded by the patent holder or licensees (Neurocentria, AIDP, Threotech); independent trials were mixed or null, which weighs on how claims are read.

Interaction with Foundational Habits

  • Sleep: Direct, uncertain. Evening dosing is common; trials found gains on a few sleep measures but not most, and time to fall asleep did not shorten (Hausenblas et al., 2024, corrected 2025). It is no substitute for consistent schedules, morning light and a cool, dark room.
  • Nutrition: Indirect. Leafy greens, nuts, seeds, legumes and whole grains supply far more magnesium than threonate servings. Taking it with meals increased threonate absorption (Wang et al., 2011); high-dose zinc or calcium taken simultaneously may compete for uptake.
  • Exercise: None known. No evidence of blunted training adaptation; sweat losses raise magnesium needs in heavy trainers. Athlete trials on sleep and recovery have no results yet (NCT07015047; NCT07640685).
  • Stress management: Indirect, possibly potentiating. One trial showed higher sleeping heart rate variability, a relaxation marker (Lopresti & Smith, 2025, corrected 2026), but anxiety scores did not change in other trials and no cortisol data exist. Breathing practice and meditation remain the primary tools.

Monitoring Protocol & Defining Success

Baseline testing before starting covers kidney function and magnesium status: serum creatinine with eGFR identifies people in whom magnesium could accumulate, and serum plus red-blood-cell magnesium set a personal reference point. A baseline record of sleep (self-rating and, if available, wearable data) and a repeatable cognitive test give the comparison needed to judge benefit, because placebo responses in threonate trials were large.

Ongoing monitoring follows a cadence of a check at 6 weeks, a full review at 12 weeks, then every 6–12 months for continued use. Kidney function and serum magnesium are repeated at 12 weeks and then annually, sooner with kidney disease, interacting drugs or symptoms such as weakness. Success is defined in advance, for example a sustained improvement on the same cognitive test or sleep measure, and use is stopped if nothing changes.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum magnesium ≥0.85 mmol/L (Costello et al.) Safety check: flags excess, or deficiency that changes use Proposed threshold from Costello et al., 2016; conventional reference range 0.75–0.95 mmol/L (same source). Reflects tissue stores poorly. Drawing at a consistent time, before the day’s dose, aids comparison; best paired with creatinine.
Red-blood-cell magnesium About 4.0–6.8 mg/dL, varying by laboratory (standard reference range) Safety check: low values change use (higher-magnesium salt added) Linked to response in one trial, though not different between groups (Liu et al., 2016). Reference ranges vary by laboratory, so using the same laboratory aids comparison.
Serum creatinine and eGFR Creatinine about 0.6–1.3 mg/dL, varying by sex and laboratory (standard reference range); eGFR: no established target, track change from the individual’s own baseline Safety check: kidneys clear magnesium; decline stops or changes use eGFR (estimated glomerular filtration rate) is calculated from creatinine. Creatinine ≥2.0 mg/dL excluded participants from the first trial (Liu et al., 2016). Heavy exercise or large meat meals the day before can raise creatinine.

Qualitative markers:

  • Sleep quality: time to fall asleep, night wakings, morning refreshment, and wearable deep-sleep estimates
  • Cognitive clarity: performance on the same memory or reaction-time test repeated under similar conditions
  • Daytime energy, alertness and mood
  • Gastrointestinal tolerance: stool consistency and abdominal comfort
  • Sleeping heart rate and heart rate variability from a wearable, if available

Emerging Research

  • Post-surgery sleep trial: A University of Miami Phase 4 (late-stage) trial (NCT06902285) is recruiting 64 joint-replacement patients for 145 mg nightly versus placebo, measuring sleep quality and daytime sleepiness; completion July 2027. A positive result would add the first independent sleep signal; a null would further weaken the sleep case.
  • Head-to-head with glycinate: A UCLA trial (NCT07640685) is recruiting 150 athletes for magnesium glycinate, Magtein or placebo for 28 days, measuring wearable sleep efficiency; completion June 2027. Superiority would support threonate’s brain-specific rationale; equivalence would favor cheaper glycinate.
  • Completed but unreported trials: A UCLA athlete trial on deep sleep and heart rate variability (NCT07015047, 109 participants) and a Barry University trial on sleep, cognition and sex differences (NCT07706283, 81 participants) completed in March 2026 with no results posted.
  • Developer dementia and dosing trials: Neurocentria’s early Alzheimer’s trial (NCT03531684, completed 2020) and older-adult dosing trial (NCT03601169, completed 2019) have no results posted, leaving the dementia question unaddressed by controlled data.
  • Schizophrenia cognition trial: A Northwestern trial (NCT02237235, completed 2017) posted working-memory T-scores (standardized scores averaging 50) of 41.8 with threonate versus 39.67 with placebo after 9 weeks, without statistical testing; it remains unpublished.
  • Menopause pilot: A Guangdong trial (NCT06959745) still lists “not yet recruiting” although its registered completion date (December 2025) has passed; its status is unclear and no results exist. A positive result would extend interest to menopausal symptoms; a null would narrow it.
  • Evening blend result: A completed University of South Carolina trial co-sponsored by Momentous (NCT06889584) found an evening threonate, L-theanine and apigenin blend did not improve sleep or stress versus placebo (Mastrofini et al., 2026).
  • Future research areas: Independent replication of cognitive effects, longer trials, direct human brain-magnesium measurement, and comparisons with other magnesium forms are the main gaps; a 2026 review called for adequately powered sleep trials (Lopresti et al., 2026). Rodent data comparing salts already challenge threonate’s uniqueness (Kumar et al., 2026).

Conclusion

Magnesium L-threonate is a form of magnesium built to reach the brain more easily, promoted mainly for memory, sleep and long-term brain health. For a health-focused adult, the main question is whether it does more than ordinary magnesium, and the evidence gives only a partial answer.

The most consistent human signal is a modest improvement in thinking and memory scores in a small number of short studies, in both younger adults with poor sleep and older adults with memory complaints. Sleep findings are weaker: most sleep scores did not beat a placebo, with gains on only a few. Mood and anxiety results are mostly flat. Strong protection of brain connections is shown only in animals, and an early study in people with dementia showed no improvement.

The risks look small. Stomach upset seems uncommon at usual doses, the main danger is magnesium building up in people with weak kidneys, and the compound can block absorption of certain antibiotics and other drugs if taken at the same time. Long-term use has not been studied.

The evidence is thin and shaped by the companies that own or sell the ingredient, which funded most favorable studies; independent hospital teams found mixed results or no benefit. Its standard servings also supply less magnesium than common forms. Taken together, it is a plausible but unproven brain-focused option whose added value over ordinary magnesium remains uncertain.

Top - Benefits - Risks - Protocol